Genome-wide Genotyping of Cerebral Cavernous Malformation Type 1 Individuals to Identify Genetic Modifiers of Disease Severity

Methods Mol Biol. 2020:2152:77-84. doi: 10.1007/978-1-0716-0640-7_6.

Abstract

Familial cerebral cavernous malformation type 1 (CCM1) is an autosomal dominant disease caused by mutations in the Krev Interaction Trapped 1 (KRIT1/CCM1) gene, and characterized by brain lesions that can cause hemorrhagic strokes, seizures, and neurological deficits. Carriers of the same genetic mutation can present with variable symptoms and severity of disease, suggesting the influence of modifier factors. Genetic modifiers of CCM1 disease severity have been recently identified and included common genetic variants in inflammatory, immune response, and oxidative stress genes and pathways. Here, we describe the genotyping of CCM1 patients with the same gene mutation (Q455X) using a high-throughput genotyping array optimized for individuals of Hispanic/Latino ancestry. We then review the quality control steps following the genome-wide genotyping. Genome-wide genotyping of larger cohorts of CCM1 patients might reveal additional genetic variants contributing to the disease severity of CCM1.

Keywords: Cerebral cavernous malformation type 1; DNA; Disease severity; Genetic modifiers; Genome-wide genotyping; Microarray; Single nucleotide polymorphism.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Alleles
  • Genes, Modifier*
  • Genetic Predisposition to Disease*
  • Genome-Wide Association Study* / methods
  • Genotype
  • Genotyping Techniques
  • Hemangioma, Cavernous, Central Nervous System / diagnosis*
  • Hemangioma, Cavernous, Central Nervous System / genetics*
  • Humans
  • Microtubule-Associated Proteins / genetics
  • Mutation
  • Severity of Illness Index

Substances

  • Microtubule-Associated Proteins